HOME >> BIOLOGY >> NEWS
PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine

Bethesda, MD, USA (December 14, 2006) In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

Supported by a $29.3 million grant to PATH from the Bill & Melinda Gates Foundation, this strategic partnership will focus on the development and manufacture of Sanaria's malaria vaccine candidateone that uses a novel, whole-parasite approach to preventing infection from the most deadly malaria parasite, Plasmodium falciparum. MVI and Sanaria will move quickly to conduct an initial safety and test-of-concept trial of the Sanaria candidate among volunteers in the United States.

"Close to one million children die of malaria each year," said Dr. Melinda Moree, Director of MVI. "With this support, we can examine another promising malaria vaccine technology and bring the field closer to delivering a safe, effective, and affordable pediatric malaria vaccine to at-risk communities in Africa."

Of the more than one million people who die of malaria every year, most of them are African children under five years old. Hundreds of millions more people suffer the effects of the mosquito-borne, parasitic disease each year. Scientists have been working for years to develop a preventive malaria vaccine and have recently demonstrated that such a vaccine is possible.

While the approach of much malaria vaccine research and development has centered on using one or more components of the malaria parasite that the human immune system can recognize, Sanaria is focused on using an attenuated, or weakened, form of the whole parasite. The idea is that when this attenuated parasite is given to individuals, they will become immune to malaria but will not get sick. This is the first vaccine candidate of its kind in the MVI portfolio.<
'"/>


14-Dec-2006


Page: 1 2

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. 20 Years of Malaria Research: Outcomes and Perspectives
7. Malaria poses additional risks for first-time mothers
8. Malaria drug may treat metabolic syndromes many symptoms
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/1/2020)... ... 2020 , ... Liver cancer, called hepatocellular carcinoma (HCC), occurs each year in ... HCC is the 5th most common cancer and the 2nd leading cause of cancer ... incidence of HCC, while China has half of all patients suffering from liver cancer. ...
(Date:1/29/2020)... ... 29, 2020 , ... VGXI, a world leading contract manufacturer ... vaccine against the novel coronavirus (2019-nCoV) that has recently emerged in Wuhan, China ... million from the Coalition for Epidemic Preparedness Innovations (CEPI) will fund the vaccine ...
(Date:1/27/2020)... DIEGO (PRWEB) , ... January 27, 2020 , ... ... Thorne as Chairman. Thorne is a noted investor, tech entrepreneur, and former senior ... as Executive Chairman of Broadline Capital, the global alternative investment firm. , ...
Breaking Biology News(10 mins):
(Date:1/22/2020)... ... January 21, 2020 , ... Microbial Discovery ... Southern Midwest Region Industrial and Institutional (I&I) Account Manager. Darrell will focus on ... , Darrell brings over 30 years of sales experience working across multiple different ...
(Date:1/10/2020)... ... January 09, 2020 , ... GenScript Biotech Corp., ... Biotech Global Forum on Jan. 14 in San Francisco, coinciding with the JP ... and the Booming China Market," will feature gene and cell therapy leaders in ...
(Date:1/7/2020)... Mass. (PRWEB) , ... January 06, 2020 , ... ... for a Digital World at The Fletcher School at Tufts University, is pleased ... Sloan Foundation. The grant will be administered by Tufts University, and will help ...
(Date:12/30/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... December ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... its new SIMS Version 1.11.19 21 CFR Part 11 compliant software program specific ...
Breaking Biology Technology:
Cached News: